The Molecular Biology of Gastrointestinal Cancer: Implications for Diagnosis and Therapy

Gastrointestinal Endoscopy Clinics of North America

Volumn 18, Issue 3, 2008, Pages 401-413

  Boland, C Richard ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; FLUOROURACIL; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P130; PROTEIN P16; PROTEIN P53; TUMOR MARKER; WNT PROTEIN;

ADENOMATOUS POLYP; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER TISSUE; CARCINOGENESIS; COLON POLYPOSIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; EPIGENETICS; ESOPHAGUS CANCER; FAMILIAL CANCER; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MOLECULAR GENETICS; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR GENE;

GASTROINTESTINAL NEOPLASMS; GENETIC MARKERS; HUMANS; MOLECULAR BIOLOGY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 47949116532     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2008.03.003     Document Type: Review

References (42)

1. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 5 (1990) 759-767
2. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 4 12 (2004) 988-993
3. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 2 (1996) 159-170
4. Vogelstein B., Fearon E.R., Kern S.E., et al. Allelotype of colorectal carcinomas. Science 244 4901 (1989) 207-211
5. Kern S.E., Fearon E.R., Tersmette K.W., et al. Clinical and pathological associations with allelic loss in colorectal carcinoma. [corrected]. JAMA 261 21 (1989) 3099-3103
6. Ionov Y., Peinado M.A., Malkhosyan S., et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 6429 (1993) 558-561
7. Aaltonen L.A., Peltomaki P., Leach F.S., et al. Clues to the pathogenesis of familial colorectal cancer. Science 260 5109 (1993) 812-816
8. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 6712 (1998) 643-649
9. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 22 (1998) 5248-5257
10. Duval A., and Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 62 9 (2002) 2447-2454
11. Maley C.C., Galipeau P.C., Finley J.C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38 4 (2006) 468-473
12. Hruban R.H., Goggins M., Parsons J., et al. Progression model for pancreatic cancer. Clin Cancer Res 6 8 (2000) 2969-2972
13. Hamilton J.P., and Meltzer S.J. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol 4 4 (2006) 416-425
14. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 392 6674 (1998) 402-405
15. Laghi L., Randolph A.E., Chauhan D.P., et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci U S A 96 13 (1999) 7484-7489
16. Del V.L., White M.K., Enam S., et al. Detection of JC virus DNA sequences and expression of viral T antigen and agnoprotein in esophageal carcinoma. Cancer 103 3 (2005) 516-527
17. Shin S.K., Li M.S., Fuerst F., et al. Oncogenic T-antigen of JC virus is present frequently in human gastric cancers. Cancer 107 3 (2006) 481-488
18. Ricciardiello L., Baglioni M., Giovannini C., et al. Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res 63 21 (2003) 7256-7262
19. Goel A., Li M.S., Nagasaka T., et al. Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology 130 7 (2006) 1950-1961
20. Ricciardiello L., Laghi L., Ramamirtham P., et al. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology 119 5 (2000) 1228-1235
21. Goel A., Arnold C.N., Niedzwiecki D., et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63 7 (2003) 1608-1614
22. Jenkins M.A., Hayashi S., O'Shea A.M., et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133 1 (2007) 48-56
23. Kane M.F., Loda M., Gaida G.M., et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57 5 (1997) 808-811
24. Lynch H.T., Boland C.R., Gong G., et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 14 4 (2006) 390-402
25. Yashiro M., Carethers J.M., Laghi L., et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 61 6 (2001) 2676-2683
26. Boland C.R., Sato J., Appelman H.D., et al. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med 1 9 (1995) 902-909
27. Grady W.M., Rajput A., Myeroff L., et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58 14 (1998) 3101-3104
28. Beach R., Chan A.O., Wu T.T., et al. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 166 4 (2005) 1069-1075
29. Jass J.R. Hyperplastic polyps and colorectal cancer: is there a link?. Clin Gastroenterol Hepatol 2 1 (2004) 1-8
30. Spring K.J., Zhao Z.Z., Karamatic R., et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 131 5 (2006) 1400-1407
31. Sieber O.M., Lipton L., Crabtree M., et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348 9 (2003) 791-799
32. Lindor N.M., Rabe K., Petersen G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293 16 (2005) 1979-1985
33. Zbuk K.M., and Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol 4 9 (2007) 492-502
34. Sweet K., Willis J., Zhou X.P., et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 294 19 (2005) 2465-2473
35. Huntsman D.G., Carneiro F., Lewis F.R., et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344 25 (2001) 1904-1909
36. Rieder H., and Bartsch D.K. Familial pancreatic cancer. Fam Cancer 3 1 (2004) 69-74
37. Wong P., Verselis S.J., Garber J.E., et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130 1 (2006) 73-79
38. Jen J., Kim H., Piantadosi S., et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331 4 (1994) 213-221
39. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 2 (2000) 69-77
40. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 3 (2003) 247-257
41. Carethers J.M., Smith E.J., Behling C.A., et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126 2 (2004) 394-401
42. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351 26 (2004) 2704-2714